PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29319171-10 2018 Two target genes of Metformin were significantly interacted with six hub genes (HADHB, NDUFS3, TAF1, MYC, HNFF4A, and MAX) with significant changes in expression values (P < 0.05, t-test). Metformin 20-29 MYC proto-oncogene, bHLH transcription factor Homo sapiens 101-104 30693913-6 2019 RESULTS Metformin treatment significantly reduced A549 or H1651 cell growth and invasive capacity in vitro as well as Ser184 phosphorylation of Bax, Ser62 phosphorylation of Myc, and Ser473 phosphorylation of Akt, all of which could be partially attenuated by OA treatment, O/E alpha4 or sh-PP2Ac. Metformin 8-17 MYC proto-oncogene, bHLH transcription factor Homo sapiens 174-177 30693913-7 2019 Metformin treatment also significantly reduced tumor formation in vivo as well as protein expression of PCNA, Akt, Myc, and serine phosphorylation of the latter 2, which can be partially blocked by O/E alpha4 or sh-PP2Ac. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 115-118 30221473-0 2018 Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 17-20 30221473-5 2018 We discovered that metformin causes a robust reduction of MYC protein level. Metformin 19-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 58-61 30221473-6 2018 Through the use of luciferase assay and coincubation with either protein synthesis or proteasome inhibitors, we demonstrated that regulation of MYC by metformin is independent of the proteasome and 3" UTR-mediated regulation, but depends on protein synthesis. Metformin 151-160 MYC proto-oncogene, bHLH transcription factor Homo sapiens 144-147 30221473-9 2018 The inhibition of MYC protein synthesis may underlie metformin"s beneficial effects on CRC risk and prognosis. Metformin 53-62 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-21 28819383-10 2017 Metformin treatment was associated with increased miR-200c expression and decreased c-Myc and AKT2 protein expression in both breast cancer cells and tumor tissues. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 84-89 29323154-8 2018 Knockdown of glutaminase 1, ASCT2, and c-Myc induced significant CSC-suppression and enhanced CSC-suppressing effect of metformin and compound 968. Metformin 120-129 MYC proto-oncogene, bHLH transcription factor Homo sapiens 39-44 29085506-8 2017 Reverse transcription-quantitative polymerase chain reaction analysis demonstrated that c-fos and c-myc expression were attenuated by metformin, an effect that was rescued in the presence of compound C. Therefore, metformin regulates the expression of ERs, and inhibits estrogen-mediated proliferation of human EC cells through the activation of AMPK and subsequent inhibition of the mTOR signaling pathway. Metformin 214-223 MYC proto-oncogene, bHLH transcription factor Homo sapiens 98-103 29088816-6 2017 More importantly, we investigated the anti-angiogenic effect of metformin, and found that metformin abrogated the ESCC microenvironment-induced transition of NECs toward TECs by inhibiting JAK/STAT3/c-MYC signaling pathway. Metformin 90-99 MYC proto-oncogene, bHLH transcription factor Homo sapiens 199-204 29383869-8 2018 While each tissue had a signature reflecting its own function, we identified a cascade of predictive upstream transcriptional regulators, including mTORC1, MYC, TNF, TGFss1, and miRNA-29b that may explain tissue-specific transcriptomic changes in response to metformin treatment. Metformin 259-268 MYC proto-oncogene, bHLH transcription factor Homo sapiens 156-159 26956973-7 2016 We observed that metformin decreased c-Myc levels, and ectopic expression of c-Myc blocked the effect of metformin on TTP expression and cell proliferation. Metformin 17-26 MYC proto-oncogene, bHLH transcription factor Homo sapiens 37-42 27760406-7 2016 The combination of 6-BT with metformin resulted in significant cytotoxicity (60-70%) in monocytic AML cell lines and was associated with inhibition of FLT3-ITD activated STAT5 and reduced c-Myc and GLUT-1 expression. Metformin 29-38 MYC proto-oncogene, bHLH transcription factor Homo sapiens 188-193 26986571-6 2016 Metformin repressed E2-inducible estrogen response element (ERE) luciferase activity, protein levels and mRNA levels of E2/ERalpha-regulated genes [including c-Myc, cyclin D1, progesterone receptor (PR) and pS2] to a greater degree than tamoxifen, resulting in inhibition of cell proliferation of MCF-7, TR MCF-7 and MDA-MB-361 cells. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 158-163 26956973-7 2016 We observed that metformin decreased c-Myc levels, and ectopic expression of c-Myc blocked the effect of metformin on TTP expression and cell proliferation. Metformin 105-114 MYC proto-oncogene, bHLH transcription factor Homo sapiens 77-82 26956973-8 2016 Our data indicate that metformin induces TTP expression by reducing the expression of c-Myc, suggesting a new model whereby TTP acts as a mediator of metformin"s anti-proliferative activity in cancer cells. Metformin 23-32 MYC proto-oncogene, bHLH transcription factor Homo sapiens 86-91 26956973-8 2016 Our data indicate that metformin induces TTP expression by reducing the expression of c-Myc, suggesting a new model whereby TTP acts as a mediator of metformin"s anti-proliferative activity in cancer cells. Metformin 150-159 MYC proto-oncogene, bHLH transcription factor Homo sapiens 86-91 26365176-6 2015 Intriguingly, no resistance was observed for the mitochondrial ROS inducer menadione and resistance could also be prevented/reversed for metformin by genetic/pharmacological inhibition of MYC. Metformin 137-146 MYC proto-oncogene, bHLH transcription factor Homo sapiens 188-191 26885449-4 2015 We found that metformin suppressed HSY cell growth in vitro in a time and dose dependent manner associated with a reduced expression of MYC onco-protein, and the same inhibitory effect of metformin was also confirmed in HSG cells. Metformin 14-23 MYC proto-oncogene, bHLH transcription factor Homo sapiens 136-139 26885449-5 2015 In association with the reduction of MYC onco-protein, metformin significantly restored p53 tumor suppressor gene expression. Metformin 55-64 MYC proto-oncogene, bHLH transcription factor Homo sapiens 37-40 26885449-6 2015 The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells. Metformin 99-108 MYC proto-oncogene, bHLH transcription factor Homo sapiens 50-53 25854169-5 2015 Cyclin D1 and c-Myc are important regulators of cancer cell growth, and we observed that treatment of thyroid cancer cells with metformin reduced c-Myc and cyclin D1 expression through suppression of mTOR and subsequent inhibition of P70S6K1 and 4E-BP1 phosphorylation. Metformin 128-137 MYC proto-oncogene, bHLH transcription factor Homo sapiens 14-19 26236947-5 2015 Intriguingly, AICAR or metformin treatment resulted in significant downregulation of MTDH expression via inhibiting c-Myc expression. Metformin 23-32 MYC proto-oncogene, bHLH transcription factor Homo sapiens 116-121 26172303-5 2015 Mechanistically, maintenance of c-Myc expression under conditions of hyperglycemia or via gene amplification facilitated metabolic escape from the effects of metformin. Metformin 158-167 MYC proto-oncogene, bHLH transcription factor Homo sapiens 32-37 26172303-6 2015 In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs. hyperglycemic mice, with increased c-Myc expression observed in metformin-treated hyperglycemic mice. Metformin 57-66 MYC proto-oncogene, bHLH transcription factor Homo sapiens 166-171 26172303-6 2015 In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs. hyperglycemic mice, with increased c-Myc expression observed in metformin-treated hyperglycemic mice. Metformin 195-204 MYC proto-oncogene, bHLH transcription factor Homo sapiens 166-171 25854169-5 2015 Cyclin D1 and c-Myc are important regulators of cancer cell growth, and we observed that treatment of thyroid cancer cells with metformin reduced c-Myc and cyclin D1 expression through suppression of mTOR and subsequent inhibition of P70S6K1 and 4E-BP1 phosphorylation. Metformin 128-137 MYC proto-oncogene, bHLH transcription factor Homo sapiens 146-151 25056111-5 2014 Low-dose metformin or SN-38 increases FOXO3 nuclear localization as well as the amount of DNA damage markers and downregulates the expression of a cancer-stemness marker CD44 and other stemness markers, including Nanog, Oct-4, and c-Myc, in these cancer cells. Metformin 9-18 MYC proto-oncogene, bHLH transcription factor Homo sapiens 231-236 25608995-9 2014 By real-time FQ-PCR tested, the expression levels of c-fos and c-myc in both cell lines gradually declined subsequent to metformin treatment at different concentrations (1, 5 and 15 mmol/L). Metformin 121-130 MYC proto-oncogene, bHLH transcription factor Homo sapiens 63-68 25608995-10 2014 As compared with the control group, the c-myc and c-fos expressions in both cell lines in metformin groups had significant differences (P < 0.05) except for the c-myc expression of the concentration of 1 mmol/L in HEC-1A cell line (P = 0.074). Metformin 90-99 MYC proto-oncogene, bHLH transcription factor Homo sapiens 40-45 26083494-10 2015 The follow-up network analyses and literature mining revealed that seven genes (CDKN1A, ESR1, MAX, MYC, PPARGC1A, SP1, and STK11) and one novel MYC-centered pathway with CDKN1A, SP1, and STK11 might play important roles in metformin"s antidiabetic and anticancer effects. Metformin 223-232 MYC proto-oncogene, bHLH transcription factor Homo sapiens 144-147 23041548-0 2012 Carbon source and myc expression influence the antiproliferative actions of metformin. Metformin 76-85 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-21 24980829-7 2014 Additionally, metformin modulated the levels of c-MYC and IRS-2, and this correlated with changes of the microRNA-33a levels. Metformin 14-23 MYC proto-oncogene, bHLH transcription factor Homo sapiens 48-53 24285728-5 2014 Finally, forcing glycolysis by metformin treatment augments this response and the efficacy of MCT1 inhibitors, suggesting an attractive combination therapy for MYC/MCT1-expressing malignancies. Metformin 31-40 MYC proto-oncogene, bHLH transcription factor Homo sapiens 160-163 23041548-5 2012 Overexpression of myc was associated with sensitization to the antiproliferative effects of metformin, consistent with myc involvement in "glutamine addiction". Metformin 92-101 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-21 22575507-6 2012 Finally, we found that metformin induced the degradation of the oncoproteins PML-RARalpha and c-Myc and activated caspase-3. Metformin 23-32 MYC proto-oncogene, bHLH transcription factor Homo sapiens 94-99 34164906-8 2021 The reduced phosphorylation of c-Myc was further decreased in the metformin-treated cells in combination with MALAT1 knock-down than metformin treatment alone. Metformin 66-75 MYC proto-oncogene, bHLH transcription factor Homo sapiens 31-36 22643892-9 2012 Downregulation of c-MYC requires AMP-activated protein kinase-signalling and mir33a upregulation by metformin. Metformin 100-109 MYC proto-oncogene, bHLH transcription factor Homo sapiens 18-23 22643892-10 2012 Ectopic expression of c-MYC attenuates the anticancer metabolic effects of metformin. Metformin 75-84 MYC proto-oncogene, bHLH transcription factor Homo sapiens 22-27 22643892-11 2012 We suggest that DICER modulation, mir33a upregulation and c-MYC targeting have an important role in the anticancer metabolic effects of metformin. Metformin 136-145 MYC proto-oncogene, bHLH transcription factor Homo sapiens 58-63 22643892-0 2012 Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 84-89 22643892-8 2012 Among the messenger RNAs downregulated by metformin, we found c-MYC, IRS-2 and HIF1alpha. Metformin 42-51 MYC proto-oncogene, bHLH transcription factor Homo sapiens 62-67 34887262-15 2021 CONCLUSION: We show that SN-38 or metformin can boost antitumor immunity in the TME by inhibiting c-Myc and STAT3 through FOXO3 activation. Metformin 34-43 MYC proto-oncogene, bHLH transcription factor Homo sapiens 98-103 34164906-8 2021 The reduced phosphorylation of c-Myc was further decreased in the metformin-treated cells in combination with MALAT1 knock-down than metformin treatment alone. Metformin 133-142 MYC proto-oncogene, bHLH transcription factor Homo sapiens 31-36 34436421-0 2021 Metformin Decreases 2-HG Production through the MYC-PHGDH Pathway in Suppressing Breast Cancer Cell Proliferation. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 48-51 34436421-7 2021 We also showed that metformin"s inhibitory effect on the PHGDH-2HG axis may occur through the regulation of the AMPK-MYC pathway. Metformin 20-29 MYC proto-oncogene, bHLH transcription factor Homo sapiens 117-120 34139918-4 2022 Areas of ongoing investigation focus on metformin"s ability to activate adenosine monophosphate kinase (AMPK), in addition to its effect on Myc mRNA, monocarboxylate transporter 1 (MCT1), hypoxia-inducible factor 1 (HIF1), mammalian target of rapamycin (mTOR), and human epidermal growth factor receptor 2 (HER2). Metformin 40-49 MYC proto-oncogene, bHLH transcription factor Homo sapiens 140-143 32382652-4 2020 Metformin and desferrioxamine are drugs that decrease c-myc; and statins increase levels of EGF. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 54-59 32208194-3 2020 Here, we attempt to find out the effect of metformin on cancer stem cell marker CD44 and stemness related transcription factors including OCT4, SOX2, NANOG, c-Myc and KLF4. Metformin 43-52 MYC proto-oncogene, bHLH transcription factor Homo sapiens 157-162 32208194-7 2020 RESULTS: Metformin showed downregulation in the gene expressions of stemness related transcription factors OCT4, SOX2, NANOG, c-Myc, and KLF4 in a dose-dependent as well as time-dependent manner. Metformin 9-18 MYC proto-oncogene, bHLH transcription factor Homo sapiens 126-131 33650651-0 2021 Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 28-33 33650651-9 2021 In addition, compared to the control treatment, metformin treatment decreased the protein levels of YAP, mTOR, p-mTOR and c-Myc. Metformin 48-57 MYC proto-oncogene, bHLH transcription factor Homo sapiens 122-127 33650651-10 2021 The overexpression of YAP alleviated the inhibitory effect of metformin on the protein expression of mTOR, p-mTOR and c-Myc. Metformin 62-71 MYC proto-oncogene, bHLH transcription factor Homo sapiens 118-123 33650651-11 2021 The combination of metformin and verteporfin markedly enhanced the effects of metformin on the protein expression of mTOR, p-mTOR and c-Myc. Metformin 19-28 MYC proto-oncogene, bHLH transcription factor Homo sapiens 134-139 33650651-11 2021 The combination of metformin and verteporfin markedly enhanced the effects of metformin on the protein expression of mTOR, p-mTOR and c-Myc. Metformin 78-87 MYC proto-oncogene, bHLH transcription factor Homo sapiens 134-139 33650651-12 2021 Therefore, the results of the present study suggest that metformin suppresses OSCC by inhibiting YAP protein expression and by suppressing the YAP-mediated effects of metformin on the protein expression of mTOR and c-Myc. Metformin 57-66 MYC proto-oncogene, bHLH transcription factor Homo sapiens 215-220 33650651-12 2021 Therefore, the results of the present study suggest that metformin suppresses OSCC by inhibiting YAP protein expression and by suppressing the YAP-mediated effects of metformin on the protein expression of mTOR and c-Myc. Metformin 167-176 MYC proto-oncogene, bHLH transcription factor Homo sapiens 215-220 33081077-6 2020 Metformin decreased the NGF-induced transcriptional activity of MYC and beta-catenin/T-cell factor/lymphoid enhancer-binding factor (TCF-Lef), as well as the expression of c-MYC, survivin and VEGF in EOC cells, while it increased miR-23b and miR-145 levels. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 64-67 33081077-6 2020 Metformin decreased the NGF-induced transcriptional activity of MYC and beta-catenin/T-cell factor/lymphoid enhancer-binding factor (TCF-Lef), as well as the expression of c-MYC, survivin and VEGF in EOC cells, while it increased miR-23b and miR-145 levels. Metformin 0-9 MYC proto-oncogene, bHLH transcription factor Homo sapiens 172-177 32641388-5 2020 The effects of metformin + 2-DG on human T cells were accompanied by significant remodeling of activation-induced metabolic transcriptional programs, in part because of suppression of key transcriptional regulators MYC and HIF-1A. Metformin 15-24 MYC proto-oncogene, bHLH transcription factor Homo sapiens 215-218 32641388-6 2020 Accordingly, metformin + 2-DG treatment significantly suppressed MYC-dependent metabolic genes and processes, but this effect was found to be independent of mTORC1 signaling. Metformin 13-22 MYC proto-oncogene, bHLH transcription factor Homo sapiens 65-68 32728616-8 2020 These findings demonstrate that c-Myc activates, whereas AMPK inhibits, TDG-mediated DNA demethylation of the SREBP1 promoter in insulin-promoted and metformin-suppressed cancer progression, respectively. Metformin 150-159 MYC proto-oncogene, bHLH transcription factor Homo sapiens 32-37